Ribavirin is currently the standard of care for treating Lassa fever. However, the human
clinical trial data supporting its use suffer from several serious flaws that render the results …

Background Research is urgently needed to reduce the morbidity and mortality of Lassa
fever (LF), including clinical trials to test new therapies and to verify the efficacy and safety of …

Effective infectious disease surveillance in high-risk regions is critical for clinical care and
pandemic preemption; however, few clinical diagnostics are available for the wide range of …

Lassa fever is a zoonotic disease identified by the World Health Organization (WHO) as
having pandemic potential. This study estimates the health-economic burden of Lassa fever …

In 2016, WHO designated Lassa fever a priority disease for epidemic preparedness as part
of the WHO Blueprint for Action to Prevent Epidemics. One aspect of preparedness is to …

Background Although early warning scores were intended to simply identify patients in need
of life-saving interventions, prediction has become their commonest metric. This review …

Abstract Lassa fever hits West African countries annually in the absence of licensed vaccine
to limit the burden of this viral hemorrhagic fever. We previously developed MeV-NP, a …

Background Viral hemorrhagic fevers (VHFs) are a group of diseases, which can be endemo-
epidemic in some areas of the world. Most of them are characterized by outbreaks, which …

Background Lassa fever is a viral haemorrhagic fever endemic to eight West African
countries. Symptomatic disease is expected to occur in 20% of those infected and …

LHF-535 is a small molecule antiviral currently in development for the treatment of Lassa
fever, a zoonotic disease endemic in West Africa that generates significant morbidity and …